Home » News » Currently Reading:

McKesson To Buy US Oncology for $2.16 Billion

November 1, 2010 News 2 Comments


McKesson announced this morning that it will buy US Oncology in a deal valued at $2.16 billion, including debt, from its private equity owners. The transaction is expected to close by December 31.

McKesson says the acquisition will have a modestly positive impact on its earnings starting in FY2012.

US Oncology, based in The Woodlands, TX, has annual revenue of around $3.5 billion and has relationships with 1,300 community-based oncologists. Its technology offerings include the iKnowMed oncology EHR, a physician collaboration portal, and clinical trials matching.

McKesson chairman and CEO John Hammergren said this about the acquisition:

McKesson is committed to improving the health and vitality of our customers, with the ultimate goal of improving the health of patients. The combination of US Oncology and McKesson will enhance our ability to achieve these goals in one of the most important segments in healthcare. Community oncology practices need strategic support that offers not only technology and distribution solutions, but also value-added clinical and reimbursement management services that enable them to provide the highest-quality, most efficient care to their patients. With this acquisition, McKesson will offer a compelling suite of services and solutions to community oncologists and other partners in the rapidly evolving specialty business.

US Oncology CEO Bruce Broussard, who will stay on to run the new McKesson unit, was quoted as saying,

With the health-care marketplace moving rapidly toward reimbursement based on quality and cost-effectiveness, our physician customers need access to deep clinical, operational and information technology capabilities to create integrated networks that continually enhance the quality of care in a cost-efficient manner. In joining McKesson, we are building the scale and expertise necessary to empower our customer base to shape the future of health care.

View/Print Text Only View/Print Text Only

HIStalk Featured Sponsors


Currently there are "2 comments" on this Article:

  1. Cancer Care is big business. Many have been enriched. Are too many patients with futile illness being sold snake oil?

Subscribe to Updates



Text Ads

Report News and Rumors

No title

Anonymous online form
Rumor line: 801.HIT.NEWS



Founding Sponsors


Platinum Sponsors




























































Gold Sponsors
















Reader Comments

  • HIT Observer: What I find most interesting here, is people defending their common practices rather than truly taking this as invaluabl...
  • Bob: There's no incentive for the provider to spend time doing a price comparison for the patient. Nor is it a good use of th...
  • Peppermint Patty: Veteran - can you clarify what was "fake "? Was something made up (definition of fake) or did you disagree with Vapo...
  • Pat Wolfram: Such a refreshing article. Thanks -- there really can be a simpler version of an acute HIT implementation. But I do ...
  • Woodstock Generation: Bravo to HIStalk's Weekender recaps and other news/opinions. I read it first thing on Monday mornings..................
  • Veteran: #fakenews...
  • Vaporware?: Secretary Shulkin: "the American healthcare system hasn’t yet figured out interoperability, but the VA can lead the wa...
  • Justa CIO: The reported go live date for McLaren Oakland is wrong. There are no dates set for activations for any locations. Post...
  • Brian Too: I admit I am partial to the quoted ICD-10-CM of "S07.9XXA Crushing injury of head, part unspecified, initial encounter....
  • Cosmos: As others in the comments section have pointed out before, GE's EMR for athletes is ironically a health record for the h...

Sponsor Quick Links